Skip to main content
// //

Daily roundup of research and analysis from The Globe and Mail’s market strategist Scott Barlow

Goldman Sachs' Weekly Kickstart report is not something I can get every week, but I really wish I could.

Written by U.S. equity strategist David Kostin, it is usually full of useful analysis.

Story continues below advertisement

This week’s report includes a list of U.S. stocks that Goldman analysts expect to continue growing profits no matter what the economic environment – secular growth stories in other words.

The list is long at 21 members, so I tried to highlight the stocks that would be most of interest to Canadian investors.

These include Netflix Inc., Twitter Inc., Monster Beverage Corp., Diamondback Energy Inc., Vertex Pharmaceuticals Inc., Intuitive Surgical Inc., Edwards Lifesciences Corp., salesforce.com Inc., Adobe Inc., Arista Networks Inc., and Mastercard Inc.

"@SBarlow_ROB GS’s “Rule of 10” U.S. stock picks. Secular growth stories" – (full table) Twitter

See also (same report): " @SBarlow_ROB From GS: Dividend growth the second worst investing strategy in in U.S. markets YTD" – (table) Twitter

***

BofA Securities analyst Lawson Winder published two reports outlining reasons to be bullish on uranium stocks, highlighting Cameco Corp. as a top pick,

Story continues below advertisement

“We are bullish Uranium (U3O8) calling it up to US$37/lb by 2022. Our normalized / long-term price is US$45/lb in 2025, 50% higher than current spot prices of US$30/lb. Global supply leaders Kazatomprom & Cameco believe that current Uranium prices are unsustainably low and have taken action (i.e. supply cuts) to balance the market… [Cameco] is one of the world’s largest uranium miners and the only publicly listed company that is involved in substantially all of the uranium value chain including mining, processing, conversion and fuel fabrication as well as developing next-generation laser enrichment technology. Among conventional uranium miners, CCO is the low cost producer… CCO is well positioned to benefit from a potential upturn in western utility contracting”

" @SBarlow_ROB BoA is bullish on uranium, Cameco" – (research excerpt) Twitter

***

Citi analyst Joanne Wuensch published a longer report on the medical technology sector.

Ms. Wuensch noted that, while COVID-19 vaccines will be the focus in the short term, research and development will create sizeable opportunities in the sector long term,

“We highlight Abbott and Boston Scientific with both benefiting from the recovering elective procedure backdrop while holding a full product pipeline and an opportunity for operating margin expansion, plus Abbott participates in the Covid-19 diagnostic environment. In Europe, we think Philips is well-positioned to meet the increased healthcare demand due to Covid-19, and concerns around its consumer business due to macro slowdown are overdone. Moreover, Philips has a lot of self-help potential to accelerate cost savings and a strong balance sheet”

Story continues below advertisement

The analyst also published a list of the industry’s most profitable companies in terms of free cahs flow. These are Johnson & Johnson, Medtronic PLC, Abbot Laboratories, Becton Dickinson and Co., Philips, Stryker Corp. (disclosure: I own this stock personally) , Baxter International Inc., Siemens AG, Edwards Lifesciences Corp. and Boston Scientific Corp.

***

Newsletter: “One of Wall Street’s most bullish pundits has changed his view. Plus, a little-known tech stock with stellar returns” – Globe Investor

Diversion: “10 great novels set within the music industry” – A Journal of Musical Things

Tweet of the Day:

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies